[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gastric-cancer-stage\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gastric-cancer-stage":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,45,74,99],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100600955","development-and-validation-of-a-risk-prediction-model-for-gastric-retention-in-patients-undergoing-sedated-gastroscopy-100600955",false,"NCT07104214","Development and Validation of a Risk Prediction Model for Gastric Retention in Patients Undergoing Sedated Gastroscopy","Development and Validation of a Risk Prediction Model for Gastric Retention in Patients Undergoing Sedated Gastroscopy: a Multicentre Prospective Cohort Study","Inclusion Criteria:\n\n* Age ≥18 years.\n* Patients scheduled for elective sedated gastroscopy or sedated gastro-colonoscopy.\n* Participant provides informed consent.\n\nExclusion Criteria:\n\n* Acute upper gastrointestinal bleeding (active hematemesis, melena, or confirmed UGIB within 24h).\n* Emergency endoscopic procedures\n* Known pregnancy or lactation\n* Subjects deemed ineligible by investigators","ALL","18 Years",{"count":19,"type":20},5000,"ESTIMATED","1 Day","OBSERVATIONAL","Gastric retention not only compromises the quality of endoscopic examination but also significantly increases the risk of reflux and aspiration in sedated patients. Aspiration of gastric contents represents a critical anesthesia-related complication during the perioperative period, carrying substantial implications for anesthetic management. With the growing volume of sedated gastroscopy procedures, predicting gastric retention has become an urgent clinical priority. This prospective study aims to establish a standardized gastric residual volume (GRV) grading system to evaluate both the volume of retained gastric contents and its contributing factors in patients undergoing upper gastrointestinal endoscopy. We will systematically assess the impact of demographic characteristics, comorbidities, and medication history on gastric emptying function. This study will facilitate establishment of an endoscopy-based simplified assessment system for gastric retention.",[25,26,27],"Gastric Cancer Stage","Esophageal Cancer","Gastroparesis",[29,30,27,31],"Gastric retention","Impaired gastric motility","Delayed gastric emptying","RECRUITING","2026-03-09",{"date":35,"type":36},"2026-03-11","ACTUAL",{"date":38,"type":36},"2025-08-03",{"date":40,"type":20},"2026-05-31",{"name":42,"class":43},"Zhejiang University","OTHER",3,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":73},"100612189","ai-assisted-detection-and-staging-of-gastric-cancer-using-contrast-enhanced-ct-100612189","NCT07250347","AI-Assisted Detection and Staging of Gastric Cancer Using Contrast-Enhanced CT","Langue and Imaging-integrated Foundation Model for Gastric Cancer Detection and Staging Via Contrast-Enhanced CT: a Multicenter Study","Inclusion Criteria:\n\n1. pathologically confirmed gastric cancer;\n2. preoperative contrast-enhanced CT performed;\n3. no evidence of distant metastasis on baseline staging;\n4. curative-intent management with complete postoperative histopathology.\n\nExclusion Criteria:\n\n1. prior treatment before surgery;\n2. non-diagnostic or poor-quality CT precluding evaluation.","85 Years",{"count":54,"type":20},8000,"Accurate preoperative assessment of gastric cancer stage guides eligibility for endoscopic resection, extent of gastrectomy and lymphadenectomy, selection for neoadjuvant therapy, and use of staging laparoscopy. Contrast-enhanced CT (CECT) is guideline-endorsed for initial staging, yet performance varies across institutions and readers. This study will evaluate an artificial-intelligence (AI) system that analyzes routine CECT to detect gastric cancer and assign four-class T stage (T1-T4) and N stage (N0-N3) .",[25,57],"Gastric Cancer Patients Undergoing Gastrectomy",[59,60,61,62,63],"Gastric cancer","stage","artificial-intelligence","detection","contrast-enhanced CT","2025-11-24",{"date":66,"type":36},"2025-11-26",{"date":68,"type":36},"2025-08-01",{"date":70,"type":20},"2028-12-30",{"name":72,"class":43},"The First Affiliated Hospital with Nanjing Medical University",1,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":84,"phases":85,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":73},"100598209","phase-3-perioperative-tislelizumab-plus-chemotherapy-versus-chemotherapy-alone-in-mhc-ii-positive-gastricgej-cancer-100598209","NCT07068516","Perioperative Tislelizumab Plus Chemotherapy Versus Chemotherapy Alone in MHC-II-Positive Gastric\u002FGEJ Cancer","A Multicenter, Randomized, Double-blind, Phase III Clinical Trial of Tislelizumab Combined With Chemotherapy Versus Placebo Plus Chemotherapy as Perioperative Treatment for MHC Class II-positive Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma","Inclusion Criteria:\n\n* Willingness to participate and signed informed consent form\n* ≥18 years old\n* Histologically confirmed gastric adenocarcinoma or gastroesophageal junction (GEJ) adenocarcinoma\n* MHC-II immunohistochemistry (IHC) 2+\u002F3+\n* Locally advanced disease (cT3-4a, N+, M0) confirmed by CT and\u002For diagnostic laparoscopy (AJCC 8th edition)\n* No previous anticancer therapy (surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy, etc.)\n* Scheduled to undergo curative resection after neoadjuvant therapy\n* Ability to swallow oral medication\n* ECOG performance status 0-1\n* Estimated survival ≥6 months\n* Hematological (without transfusion\u002FG-CSF support within 14 days):ANC ≥1.5×10⁹\u002F, Platelets ≥80×10⁹\u002FL, Hemoglobin ≥80 g\u002FL. Hepatic\u002FRenal: Total bilirubin \\\u003C1.5×ULN, ALT\u002FAST ≤2.5×ULN, Serum creatinine ≤1.5×ULN or CrCl \\>50 mL\u002Fmin (calculated by Cockcroft-Gault formula: Male: CrCl = \\[(140-age) × weight (kg)\\] \u002F (72 × serum Cr \\[mg\u002FdL\\]), Female: CrCl = \\[(140-age) × weight (kg)\\] \u002F (72 × serum Cr \\[mg\u002FdL\\]) × 0.85.\n* Contraception Requirements: Female participants of childbearing potential: Negative serum pregnancy test within 7 days before enrollment; agreement to use highly effective contraception during treatment and for 120 days after last dose. Female participants of childbearing potential: Negative serum pregnancy test within 7 days before enrollment; agreement to use highly effective contraception during treatment and for 120 days after last dose.\n\nExclusion Criteria:\n\n* Tumors deemed unresectable due to disease extent, surgical contraindications, or patient refusal.\n* Known microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) tumors.\n* History of or concurrent other malignancies (except adequately treated non-melanoma skin cancer or carcinoma in situ).\n* Chronic or clinically significant conditions that may compromise treatment tolerance (e.g., severe cardiac disease, uncontrolled hypertension, significant hepatic\u002Frenal dysfunction).\n* History of gastrointestinal perforation, intra-abdominal abscess, or bowel obstruction within 3 months (or clinical\u002Fradiologic suspicion of obstruction).\n* Presence of active ulcers, non-healing wounds, or fractures.\n* Arterial\u002Fvenous thrombosis within 6 months (e.g., stroke, transient ischemic attack, deep vein thrombosis, pulmonary embolism).\n* Urinalysis showing ≥++ protein with confirmed 24-hour urine protein \\>1.0 g.\n* Requiring systemic antibiotics, antivirals, or antifungals.\n* Hepatitis B: HBsAg-positive with HBV DNA ≥500 IU\u002FmL. Hepatitis C: HCV antibody-positive with HCV RNA above ULN.\n* Congenital or acquired (e.g., HIV infection).\n* Active autoimmune disease or history of autoimmune disease with relapse potential.\n* Prior or planned organ\u002Fallogeneic bone marrow transplantation.\n* Interstitial lung disease (ILD), history of steroid-treated ILD, active pneumonia on screening CT, or active tuberculosis.\n* Current or recent use of immunosuppressants or systemic corticosteroids (except physiologic replacement doses).\n* Received live attenuated vaccines within 28 days before treatment or requiring them during\u002Fwithin 60 days post-treatment.\n* Known allergy to any study drug or excipients.\n* Currently breastfeeding.\n* Any condition that, per investigator judgment, may jeopardize patient safety or study completion.","80 Years",{"count":83,"type":20},470,"INTERVENTIONAL",[86],"PHASE3","Investigators has conducted a series of studies on patient selection for perioperative immunotherapy in locally advanced gastric cancer. Results from prospective single-arm trial (NCT05739045) demonstrated that 21.74% of patients achieved pathological complete response (pCR) after receiving neoadjuvant nivolumab combined with SOX regimen. Notably, investigators identified that the sensitive group exhibited upregulated MHC-II expression in malignant cells at baseline, with enriched pathways including interferon-gamma signaling and MHC class II antigen presentation. The pCR rate was significantly higher in MHC-II positive patients compared to MHC-II negative patients (36.84% vs 11.11%, P=0.038). Subsequent retrospective analyses and another prospective single-arm study focusing on MHC-II positive populations consistently showed superior short-term treatment outcomes with immunotherapy plus chemotherapy in this subgroup.\n\nBuilding upon these preliminary findings from small-scale studies and considering current developments in the field, we are now initiating this multicenter, randomized, double-blind, placebo-controlled phase III clinical trial. The study aims to evaluate the efficacy and safety of tislelizumab combined with chemotherapy versus placebo plus chemotherapy as perioperative treatment for MHC-II positive patients with locally advanced gastric or gastroesophageal junction adenocarcinoma.",[25],"NOT_YET_RECRUITING","2025-07-06",{"date":92,"type":36},"2025-07-16",{"date":94,"type":20},"2025-07-20",{"date":96,"type":20},"2030-06-30",{"name":98,"class":43},"Xiangdong Cheng",{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":108,"conditions":109,"keywords":110,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":73},"100478296","multi-parametric-mri-and-dual-energy-ct-in-patients-of-gastric-cancer-100478296","NCT05508126","Multi-parametric MRI and Dual-energy CT in Patients of Gastric Cancer","Diagnostic Accuracy of Multi-parametric MRI and Dual-energy CT in Gastric Cancer: a Paired Validating Confirmatory Study","Inclusion Criteria:\n\n* Consecutive patients with preoperative pathologically confirmed GC by endoscopy and preoperative imaging data (DECT\u002FmpMRI) were included.\n* No contraindications for CT\u002FMRI examination\n* Written informed consent\n\nExclusion Criteria:\n\n* Patients with a history of previous therapy.\n* Patients with recurrent gastric cancer\n* Patients with a history of severe allergy to contrast agents\n* Patients with imaging artefacts affect the evaluation",{"count":107,"type":20},222,"Accurate preoperative staging of gastric cancer is of major importance for guiding therapeutic decision-making, preventing both under- and over-treatment. The purpose of this study is to investigate the diagnostic performance of the Multi-parametric magnetic resonance imaging (mpMRI) and dual-energy computed tomography (DECT) in gastric cancer.",[25],[111,112],"Computed Tomography","Magnetic Resonance Imaging","2024-10-10",{"date":115,"type":36},"2024-10-15",{"date":117,"type":36},"2021-11-01",{"date":119,"type":20},"2026-12-31",{"name":72,"class":43}]